Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | HRH1 | P35367 | 2/20 | 0.53 |
| ▸ | TBXAS1 | P24557 | 7/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.43 |
| ▸ | PTAFR | P25105 | 2/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL742307 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1HRH1TBXAS1CYP2A6 | |
| SCHEMBL8662158 | 0.99 | L3MBTL1 (0.55) | L3MBTL1TDP1HRH1TBXAS1CYP2A6 | |
| SCHEMBL17760802 | 0.83 | IDO1 (0.46) | L3MBTL1TDP1 | |
| SCHEMBL6558611 | 0.83 | IDO1 (0.46) | L3MBTL1TDP1 | |
| SCHEMBL16307320 | 0.83 | IDO1 (0.46) | L3MBTL1TDP1 | |
| SCHEMBL16784080 | 0.83 | IDO1 (0.46) | L3MBTL1TDP1 | |
| SCHEMBL4957807 | 0.82 | HRH1 (0.47) | HRH1NPC1RAB9AHRH4HRH3 | |
| SCHEMBL17398452 | 0.82 | IDO1 (0.47) | L3MBTL1TDP1 | |
| SCHEMBL2092004 | 0.79 | TDP1 (0.64) | L3MBTL1TDP1HRH1TBXAS1CYP2A6 | |
| SCHEMBL5398670 | 0.79 | CHRNB2 (0.44) | L3MBTL1TDP1CYP2A6NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120123113-A1 | DI-SUBSTITUTED PYRIDINUM POLYMERS AND SYNTHESIS THEREOF | UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2012-05-17 | — | — | US | disclosed |
| US-20120123113-A1 | DI-SUBSTITUTED PYRIDINUM POLYMERS AND SYNTHESIS THEREOF | UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2012-05-17 | — | — | US | disclosed |
| EP-2430074-A1 | DI-SUBSTITUTED PYRIDINIUM POLYMERS AND SYNTHESIS THEREOF | University Court Of The University Of Aberdeen (GB) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010086652-A1 | DI-SUBSTITUTED PYRIDINIUM POLYMERS AND SYNTHESIS THEREOF | UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120123113-A1 | DI-SUBSTITUTED PYRIDINUM POLYMERS AND SYNTHESIS THEREOF | PDXK, RAD54L, CDKL5 | L3MBTL1 4246/4885TDP1 3812/4885HRH1 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.